How to make Pharmacy “The Easy Part” of the patient experience. Anyone who’s ever been a hospital patient, or patient caregiver, knows that the mental strain of a serious illness can often match the negative impact of the physical trauma. Particularly when an illness is chronic and/or long-term, the stress involved in managing the details … Read More
Before we begin, we’re going to be honest with you. A significant component of VytlOne’s business is guiding 340B health systems through the process of building, accrediting, funding, launching and managing on-campus specialty pharmacies. Many times in this space, we’ve maintained that every 340B hospital should consider owning a specialty pharmacy. We’re currently in the … Read More
We all know the 340B Drug Pricing Program was designed to enable eligible healthcare organizations to stretch scarce federal resources in serving underserved patients and expanding their missions in the community services. What we at VytlOne have learned in supporting the 340B programs of more than 100 health systems and health centers is that, properly … Read More
POST OUTLINE Introduction: Overview Review of Johnson & Johnson’s drug rebate payments in 2023 J&J’s 2023 profit margin Johnson & Johnson’s real rebate problem 340B and the drug industry as a whole Estimated percentage of drug sales supporting 340B health systems Why the actual number is lower than reported The importance of 340B savings & … Read More
It’s no secret that the 340B Drug Pricing Program has been a lifeline for eligible health systems, enabling them to fill-in the massive revenue gaps inherent to the non-profit-hospital business model (and, in the process, support their mission of providing quality care to our nation’s most vulnerable patients) through access to discounted prescription refills. At … Read More
Based on our experience, it’s a claim we can make with 100% certainty. VytlOne has supported the 340B programs of more than 100 health systems and health centers since 2019. Altogether, we’ve generated nearly $1 billion in pharmacy-related savings for our clients. While the average 340B hospital’s revenues have decreased significantly since the 2020 advent … Read More
Since the advent of 340B ESP in 2020, drug manufacturers have imposed a raft of unlawful restrictions on 340B program savings. Nowhere have those restrictions been more punitive than with specialty pharmacy medications; drugs which typically represent the most expensive (and profitable) in manufacturers’ product lines. 340B restrictions from the drug manufacturers’ perspective That said, … Read More
Based on our experience, it’s a claim we can make with 100% certainty. Since 2019, when VytlOne launched its 340B Support Services division, we’ve managed the 340B programs of 18 health systems. We’ve generated more than $500 million in 340B Savings and Revenue. And yet, we’ve never served (or seen) a 340B health system with … Read More
The 340B-program landscape has changed dramatically. For the 340B program’s first 28 years after its 1992 inception, the basic list of Best Practices for eligible entities (the 340B basics, if you will) remained largely unchanged — aside from the dramatically-increased importance of using specialized software. But since the June, 2020 introduction of 340B ESP — … Read More
In the fall of 2022, VytlOne set-out to extend its pharmacy-based services to hospitals, their affiliated physicians and their patients by offering a multi-benefit prescription savings card. One that helps make unaffordable drugs more affordable, while increasing patients’ access to medications through prescription discounts. Just as importantly, a card that gives participating health systems access … Read More
